Erectile dysfunction Pipeline Summary

DelveInsight’s, “Erectile dysfunction - Pipeline Insight, 2026” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Erectile dysfunction pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Erectile dysfunction: Understanding

Erectile dysfunction: Overview

Erectile dysfunction (ED) is the persistent inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. It is one of the most common male sexual disorders, with prevalence increasing with age, although it can affect men of all ages. ED significantly impacts quality of life, self-esteem, and interpersonal relationships and is often associated with underlying systemic diseases.

ED is a multifactorial disorder with vascular, neurological, hormonal, psychological, and medication-related causes. Common risk factors include diabetes mellitus, cardiovascular disease, hypertension, hyperlipidemia, obesity, smoking, metabolic syndrome, depression, anxiety, pelvic surgery, and certain medications. Lifestyle factors such as excessive alcohol consumption, physical inactivity, and illicit drug use may also contribute to its development.

The pathophysiology of ED primarily involves impaired penile blood flow and dysfunction of the nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway. Reduced NO release or endothelial dysfunction prevents adequate relaxation of the corpus cavernosum smooth muscle, limiting arterial blood inflow and trapping of blood within the penis. Neurological injury, hormonal deficiencies, and structural changes in penile tissue can further impair the normal erectile response.

Diagnosis of ED is based on a detailed medical, sexual, and psychosocial history, along with a focused physical examination. Initial laboratory evaluation typically includes blood glucose, lipid profile, and serum testosterone measurements to identify underlying metabolic or hormonal abnormalities. Additional investigations, such as penile Doppler ultrasonography, nocturnal penile tumescence testing, or neurological assessments, may be performed when the etiology remains unclear or before advanced treatment options.

Management of ED begins with lifestyle modifications and treatment of underlying medical conditions and reversible risk factors. Oral phosphodiesterase type 5 (PDE5) inhibitors are the first-line pharmacological therapy for most patients. Alternative treatments include testosterone replacement therapy for hypogonadal men, vacuum erection devices, intracavernosal or intraurethral vasoactive agents, psychosexual counseling, and penile prosthesis implantation for patients who do not respond to or are unsuitable for conservative therapies.

"Erectile dysfunction- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Erectile dysfunction pipeline landscape is provided which includes the disease overview and Erectile dysfunction treatment guidelines. The assessment part of the report embraces, in depth Erectile dysfunction commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Erectile dysfunction collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Erectile dysfunction R&D. The therapies under development are focused on novel approaches to treat/improve Erectile dysfunction.

Erectile dysfunction Emerging Drugs Chapters

This segment of the Erectile dysfunction report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Erectile dysfunction Emerging Drugs

• LIB01: Dicot AB

LIB-01 is an investigational first-in-class oral small-molecule therapy developed by Dicot AB for the treatment of erectile dysfunction. It is a semi-synthetic compound derived from a naturally occurring plant-based substance and is designed to restore erectile function through a mechanism distinct from phosphodiesterase type 5 (PDE5) inhibitors. Its proposed mechanism of action involves modulation of neural and vascular pathways regulating penile erection, including effects on the endogenous melanocortin signaling pathway (MC4R), and thereby enhancing erectile responses with the potential for prolonged therapeutic benefit. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Erectile dysfunction.

• BlueC-231: Blue Cell Therapeutics

BlueC-231 is an investigational allogeneic mesenchymal stem cell therapy which is designed to address the underlying causes of ED by promoting angiogenesis, repairing endothelial cells, vascular smooth muscle, and damaged nerves, while also reducing inflammation. Its mechanism of action is based on the secretion of angiogenic factors (e.g., VEGF) and neurotrophic factors that stimulate blood vessel formation and nerve regeneration, thereby restoring erectile function rather than providing temporary symptomatic relief. Currently, the drug is being evaluated in the Preclinical stage of its development for the treatment of Erectile dysfunction.

Further product details are provided in the report……..

Erectile dysfunction: Therapeutic Assessment

This segment of the report provides insights about the different Erectile dysfunction drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Erectile dysfunction

There are approx. 10+ key companies which are developing the therapies Erectile dysfunction. The companies which have their Erectile dysfunction drug candidates in the most advanced stage, i.e. Phase II include, Dicot AB and others.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Erectile dysfunction pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Erectile dysfunction: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Erectile dysfunction therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Erectile dysfunction drugs.

Erectile dysfunction Report Insights

• Erectile dysfunction Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Erectile dysfunction Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Erectile dysfunction drugs?
• How many Erectile dysfunction drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Erectile dysfunction?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Erectile dysfunction therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Erectile dysfunction and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Dicot AB
• Blue Cell Therapeutics
• Can-fite Biopharma
• Beijing Inno Medicine Co., Ltd.

Key Products

• LIB01
• BlueC-231
• CF602
• YN001